Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD) also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). The incidence and prevalence of NMOSDranges from 0.05–0.40 and 0.52–4.4 per 100,000 people respectively

“Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years. Neuromyelitis Optica Spectrum Disorder Key players such as – Neuromyelitis optica: Imcyse, Aeterna Zentaris, BioThera Solutions, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment 

• Neuromyelitis Optica Spectrum Disorder Emerging therapies such as – Research Programme, AIM Biologicals, BAT4406F, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.   
• In May 2022, Alexion Pharmaceuticals announced that ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
• In July 2020, Imcyse received funding for its Neuromyelitis Optica Spectrum Disorder (NMOSD) programme in the amount of 1.1 million Euros spread over 29 months. Willy Borsus, Minister of Economics and Research, approved funding on behalf of the Walloon Region. In order to choose and determine the clinical relevance of the NMOSD Imotope, the subsidy will be utilised to demonstrate Proof of Concept (PoC) both in an animal model and on human cells (Phase 0 study). An NMOSD patient Phase I clinical trial will come next

Route of Administration

Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Oral
• Subcutaneous
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Immunoglobulin
• Monoclonal antibodies
• Protein
• Recombinant fusion proteins
• Small molecules
• Vaccine
• Product Type

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment

• Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
• Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
• Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
• Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
• Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
• Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight’s Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:

Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are – Imcyse, TG Therapeutics, Nihon Pharmaceutical, Alexion Pharmaceuticals, Boston Pharmaceuticals, Bio-Thera Solutions, Reistone Biopharma, RemeGen, and others.

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:

• Research Programme: Neuromyelitis optica: Imcyse
• AIM Biologicals: Aeterna Zentaris
• BAT4406F: BioThera Solutions
• HBM9161: Harbour BioMed
• SHR1459: Reistone Biopharma
• Telitacicept: RemeGen
• Ravulizumab: Alexion Pharmaceuticals

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:

The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
• Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers

• Increase in Neuromyelitis Optica Spectrum Disorder prevalence
• Rising awareness among general population about Neuromyelitis Optica Spectrum Disorder
• Emergence of novel therapies

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers

• Dearth of skilled professionals and lack of healthcare infrastructure in developing economies
• High costs for Neuromyelitis Optica Spectrum Disorder treatment

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight    

• Coverage: Global
• Key Neuromyelitis Optica Spectrum Disorder Companies: Neuromyelitis optica: Imcyse, Aeterna Zentaris, BioThera Solutions, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others
• Key Neuromyelitis Optica Spectrum Disorder Therapies: Research Programme, AIM Biologicals, BAT4406F, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others
• Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
• Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers 

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis